Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear
neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Repertaxin
is a novel, specific inhibitor of CXCL8. This study is configured to explore the safety and
efficacy of repertaxin in preventing the primary graft dysfunction (PGD) after lung
transplantation.